KRAS and familial pancreatic carcinoma: First, even though a meta‐analysis of KRAS mutations in pancreatic cancer reported poorer prognosis,26 the cohorts used in the meta‐analyses included fewer cases with KRAS mutation (60%–70% cases) compared to other studies that usually report a 90% prevalence of KRAS mutations.